MK-2206 2HCl

目录号:S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂,在无细胞试验中IC50分别为8 nM/12 nM/65 nM;对250种其他蛋白激酶没有抑制活性。Phase 2。

规格 价格 库存 购买数量  
RMB 1789.01 现货
RMB 895.01 现货
RMB 1403.57 现货
RMB 3032.85 现货
RMB 4655.02 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献181篇:

客户使用该产品的20个实验数据:

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

    The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

  • Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

    VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

  • Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

    A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

  • MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

     

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

产品安全说明书

Akt抑制剂选择性比较

生物活性

产品描述 MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂,在无细胞试验中IC50分别为8 nM/12 nM/65 nM;对250种其他蛋白激酶没有抑制活性。Phase 2。
特性 MK-2206是第一个进入临床研究阶段的Akt小分子变构抑制剂。
靶点
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
体外研究

MK-2206是变构抑制剂,由pleckstrin同源结构域激活。MK-2206抑制Akt的苏氨酸308位点和丝氨酸473位点的自身磷酸化作用。另外,MK-2206阻止Akt调节的下游信号分子(包括TSC2, PRAS40,及核糖体S6蛋白)的磷酸化作用。与抑制Ras 突变型细胞系(如NCI-H358, NCI-H23, NCI-H1299, 和Calu-6)相比,MK-2206 更有效地抑制Ras野生型细胞系(如A431, HCC827, 和NCI-H292)。MK-2206和细胞毒素药剂如erlotinib 和lapatinib联用作用于肺部NCI-H460肿瘤细胞或者卵巢A2780肿瘤细胞,MK-2206也显示出协同效应。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MUjDfZRwfG:6aXOgRZN{[Xl? M3TzSFMh|ryP NIrRT2E4OiCq NWHMPWVvTE2VTx?= M3vxeGlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w MWCyNFU4OTB4OR?=
A431 NHrIXXlMcW6jc3WgRZN{[Xl? MV:1JO69VQ>? Mnn5OUBp NXrTdmhwTE2VTx?= NWT3bJJxW3WycILld5NmeyC2aHWgd4lodmGuaX7nJI9nKEGtdDDhcoQhTXKt NVL0S|Z7OjB3N{GwOlk>
HepG2 NV[xbWlGS3m2b4TvfIlkKEG|c3H5 NULDbHJ[OTBizszN M4XCd|I1KGh? MUDEUXNQ MVXT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= M3\je|IyOjB3OUK1
Sk-Hep1 NHSxU41EgXSxdH;4bYMhSXO|YYm= MoTUNVAh|ryP M1HsXVI1KGh? M3LPdmROW09? Mk\LV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni M1nVZ|IyOjB3OUK1
OCUT1 cells harbored PIK3CA (H1047R+/+) Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKzJO69VQ>? M4fGR|Uh\A>? NUPnXXZ[TE2VTx?= MYPJR|UxRTBwMUSg{txO M4T1ZVIyOjh7Mk[3
K1 cells harbored PIK3CA (E542K+/+) NF7ZTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDBTHBbOyEQvF2= M2r2bVUh\A>? MX7EUXNQ MkPMTWM2OD1yLkWyJO69VQ>? NIi3VHozOTJ6OUK2Oy=>
FTC133 cells harbored PTEN (allele deletion and R130+) M{L0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjwV5o{KM7:TR?= M{TZe|Uh\A>? NXv6fYwyTE2VTx?= MlLXTWM2OD1yLkG4JO69VQ>? MU[yNVI5QTJ4Nx?=
C643 cells harbored HRAS (G13R+/−) NVz6elZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LLOlMh|ryP M1myUVUh\A>? NYrR[WpITE2VTx?= M4PPbGlEPTB;MD6yO{DPxE1? NF\YbHUzOTJ6OUK2Oy=>
Hth7 cells harbored NRAS (Q61R+/−) NUDLN|ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r5bVMh|ryP Mo\ZOUBl MW\EUXNQ MlfvTWM2OD12LkWg{txO M1H1ZVIyOjh7Mk[3
TPC1 cells harbored RET/PTC1 rearrangement NULsdlZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHLN{DPxE1? NHLvbWU2KGR? MYTEUXNQ NGDzfHhKSzVyPUCuOVkh|ryP NWPDfJdrOjF{OEmyOlc>
Hth74 M33HSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OxZVMh|ryP MVK1JIQ> NVW4PHFHTE2VTx?= NYjBTG01UUN3ME2yMlE6KM7:TR?= NXvFWYNUOjF{OEmyOlc>
KAT18 NEGybFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzRN{DPxE1? MluxOUBl M1:2d2ROW09? MV7JR|UxRTRwNkKg{txO M{jHVlIyOjh7Mk[3
SW1736 NFfnd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX6UHNnOTByIN88US=> M4\EO|Uh\A>? M1fnTGROW09? MmjQTWM2OD12Nz61OkDPxE1? M2T5XlIyOjh7Mk[3
WRO NX75bpFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvxbm1pOTByMDFOwG0> MYG1JIQ> MkDrSG1UVw>? NFzpbpNKSzVyPkGwNFAh|ryP NWfLVlA4OjF{OEmyOlc>
TAD2 MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PvVVExODBizszN M3yyfFUh\A>? MV;EUXNQ MkHwTWM2OD5zMECwJO69VQ>? MXiyNVI5QTJ4Nx?=
LN229 M1vmU2Fxd3C2b4Ppd{BCe3OjeR?= MkW4NE42KM7:TR?= NXfyTm5vPjBiaB?= M1z0TWROW09? M4SzOmF2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmk M1nJc|IzODV5OUG0
T98G M1XjZ2Fxd3C2b4Ppd{BCe3OjeR?= M3XhW|AvPSEQvF2= NWHtbZd6PjBiaB?= NGnEUo9FVVOR MWnBeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>? NWrKOYR3OjJyNUe5NVQ>
HC11 M3e2emZ2dmO2aX;uJGF{e2G7 MYCxNEDPxE1? M3W0VlI1KGh? M3HyU2ROW09? NIjZOW5KdmirYnn0d{DPui2lYYPlbY4h[W6mIFHEVnAhe3mwdHjld4l{ NITCb3czOjR{Nk[yNS=>
MOLT-4 NFG4e4VEgXSxdH;4bYMhSXO|YYm= NHPzbIIyOCEQvF2= MlHhOFghcA>? M3PCO2ROW09? NEjjXohKSzVyPUGuO-KBkc7:TR?= M3zJblIzPjF2MkSz
CEM-R MmKwR5l1d3SxeHnjJGF{e2G7 NInvcZQyOCEQvF2= M{\iR|Q5KGh? M1XiU2ROW09? M1[5bGlEPTB;Mz6z5qCK|ryP NVLFeHhsOjJ4MUSyOFM>
CEM-S Ml7HR5l1d3SxeHnjJGF{e2G7 NHLBNFAyOCEQvF2= NELvTmM1QCCq NH\wbmpFVVOR M2PWPWlEPTB;NT6x5qCK|ryP MofGNlI3OTR{NEO=
MOLT-4 NFLtWI9HfW6ldHnvckBCe3OjeR?= MXexNEDPxE1? MYeyOEBp Mn;1SG1UVw>? NFPiSYRDdG:la4OgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOnIH;mJJRp\SClZXzsJIN6[2yn NYPUN4psOjJ4MUSyOFM>
MOLT-4 M{nZcmZ2dmO2aX;uJGF{e2G7 Mlv6OQKBkc7:TR?= Mo\POEBp M3\1S2ROW09? MYTJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFM1GvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> MomwNlI3OTR{NEO=
CEM-R MnG5SpVv[3Srb36gRZN{[Xl? NF;rRY816oDLzszN NVfUUGwyPCCq MX;EUXNQ M1X1fWlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO0RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? MofHNlI3OTR{NEO=
CEM-S MUHGeY5kfGmxbjDBd5NigQ>? NEHzeJY16oDLzszN NET0fIE1KGh? M1ToWGROW09? NXH4RVY{UW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|VCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ Mn3vNlI3OTR{NEO=
HepG2 cell NEjaXGJMcW6jc3WgRZN{[Xl? NWTjV3NiOjBizszN MmK4NlQhcA>? NWHEV29oTE2VTx?= MUXEc5dvemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gRWtV MoWyNlM4QTd|MUm=
HepG2 cell NVnUdpNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLr[JZIOzBizszN MlLCNlQhcA>? MYrEUXNQ NHe0fIdKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NUXEZVZ3OjN5OUezNVk>
HepG2 cell MoXERZBweHSxc3nzJGF{e2G7 MXqyNEDPxE1? MUCyOEBp MmXvSG1UVw>? MmjuTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NUXITm1POjN5OUezNVk>
GEO NHjQfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P0Z|UxOCCwTR?= NEXl[I44OiCq MnvISG1UVw>? M2jkW2lvcGmkaYTzJINmdGxiZ4Lve5Rp MkD6NlQ2QDF{M{G=
CNE-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[xNEDPxE1? Ml7iPVYhcA>? M1ixXmROW09? MWnJR|UxRTJwOU[g{txO MVmyOVM{Pjl{NR?=
CNE-2 M{nq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fSU|ExKM7:TR?= NUXl[m1bQTZiaB?= NXG0dYw6TE2VTx?= M2rpSWlEPTB;ND61N{DPxE1? NGLmVJkzPTN|NkmyOS=>
HONE-1 M4HGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fOZ|ExKM7:TR?= NEew[oI6PiCq MnrHSG1UVw>? MmH5TWM2OD1|LkO3JO69VQ>? NUO2fZdnOjV|M{[5NlU>
SUNE-1 M3HaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoezNVAh|ryP NYLCO4MzQTZiaB?= MVXEUXNQ NIXqWIJKSzVyPUCuOVIh|ryP NWLXfHpSOjV|M{[5NlU>
CNE-2 MlvISpVv[3Srb36gRZN{[Xl? MUOxNEDPxE1? NGKyWmo1QCCq M2ThOGROW09? NWm5N3NJUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?= M1HCTlI2OzN4OUK1
HONE-1 M{HYSWZ2dmO2aX;uJGF{e2G7 M1i4V|ExKM7:TR?= NUfQO3RFPDhiaB?= NIfuWpBFVVOR NXq1emFLUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?= NHyzToMzPTN|NkmyOS=>
NEC8 MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkGwTWM2OD1yLkC5OlUyKM7:TR?= NIXnOplUSU6JRWK=
P12-ICHIKAWA NYfKe3h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELaenVKSzVyPUCuNVE3OiEQvF2= M1nVZXNCVkeHUh?=
MDA-MB-175-VII MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDrN4M2UUN3ME2wMlE{PzN6IN88US=> M325cXNCVkeHUh?=
AsPC-1 NV\tbGFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMkKxNlIh|ryP NXe3V4NQW0GQR1XS
T47D Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfUTWM2OD1yLkK4NlUh|ryP M3vkTHNCVkeHUh?=
HH MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwM{CyPFMh|ryP NUTHfmJPW0GQR1XS
MOLT-16 NHvRc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwM{CzNkDPxE1? MWXTRW5ITVJ?
ES5 MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PuTWlEPTB;MD6zOFQ2PSEQvF2= MlLzV2FPT0WU
RS4-11 NI\VcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G1c2lEPTB;MD6zOFYyKM7:TR?= NUj0XIFkW0GQR1XS
KARPAS-45 MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPwc2VTUUN3ME2wMlM4OzJzIN88US=> M3vhXXNCVkeHUh?=
NCI-H720 NWTpS2pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwM{e2O|kh|ryP MX\TRW5ITVJ?
H9 NGX4eYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPDfmIyUUN3ME2wMlM5QDh|IN88US=> MVzTRW5ITVJ?
EFM-19 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInPVFlKSzVyPUCuOFQxOSEQvF2= NITERoJUSU6JRWK=
SBC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HKT2lEPTB;MD60OFA{PSEQvF2= NUXtTpppW0GQR1XS
A4-Fuk NVzXTGtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvvRpY5UUN3ME2wMlQ3QDZ6IN88US=> M4nZdnNCVkeHUh?=
NCI-H1563 NGjzcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\VSItLUUN3ME2wMlQ5OTh7IN88US=> NGnxfHFUSU6JRWK=
HCC1419 NG\EPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHFN|RDUUN3ME2wMlQ5QDl{IN88US=> NWq2eFFMW0GQR1XS
H-EMC-SS MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFixNW9KSzVyPUCuOFk6OzlizszN NGm4S2ZUSU6JRWK=
BHT-101 NHfPe|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwNUK5OlEh|ryP MmXmV2FPT0WU
IGROV-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV24fI1WUUN3ME2wMlU2OjR7IN88US=> NGjwUnZUSU6JRWK=
HGC-27 M{XPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rtcWlEPTB;MD61Olc5OyEQvF2= NH65N21USU6JRWK=
MDA-MB-361 NW\ESWUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PVXGlEPTB;MD61O|c3OSEQvF2= M4\ONnNCVkeHUh?=
KE-37 M3WwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XTO2lEPTB;MD61PFI3KM7:TR?= Mmf6V2FPT0WU
HCC70 NFnqU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXWfnZHUUN3ME2wMlU6QDJ5IN88US=> MYPTRW5ITVJ?
LNCaP-Clone-FGC MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7Cfm9KSzVyPUCuOlExPDhizszN Mnv2V2FPT0WU
HAL-01 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwNkKxN{DPxE1? NX3qcGh[W0GQR1XS
HT NVf5RplLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILqfHdKSzVyPUCuOlMzOzlizszN MkTuV2FPT0WU
MDA-MB-415 NG\DZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17vVGlEPTB;MD62N|YzPiEQvF2= NY\pV3BHW0GQR1XS
NOS-1 NF;VUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNkO3NlMh|ryP NYrBT|k{W0GQR1XS
DU-145 NH\3NWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW3TWM2OD1yLk[0O|Q2KM7:TR?= NGH6Vm5USU6JRWK=
OCUB-M M160bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf0ZnRKSzVyPUCuO|A6PjZizszN NXnPVXRKW0GQR1XS
VA-ES-BJ Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z3bWlEPTB;MD63N|AzPSEQvF2= MVnTRW5ITVJ?
J-RT3-T3-5 M{L6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnlTWM2OD1yLke0OFA{KM7:TR?= NFrN[|ZUSU6JRWK=
MOLT-4 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX0[ZlxUUN3ME2wMlgxPTh{IN88US=> MYHTRW5ITVJ?
NB7 NFzMXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;RTWM2OD1yLkiyOFEyKM7:TR?= MlzPV2FPT0WU
L-363 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLQNGZqUUN3ME2wMlg{PDR{IN88US=> MYnTRW5ITVJ?
NKM-1 M2rxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke0TWM2OD1yLki2NlU{KM7:TR?= MnXoV2FPT0WU
HOP-92 NYnHNpYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwOEeyNlMh|ryP MX7TRW5ITVJ?
OAW-42 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MliyTWM2OD1yLki4O|Ih|ryP MXrTRW5ITVJ?
HuO9 NYHE[Zo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r5fWlEPTB;MD65Nlc2OSEQvF2= NYD0dXYyW0GQR1XS
MFE-280 M13DZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwOU[0OlUh|ryP MlTZV2FPT0WU
EM-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz2TWM2OD1yLkm3PVM6KM7:TR?= MonUV2FPT0WU
NCI-H520 NYPrXG5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\MS|ZKSzVyPUCuPVg2QTJizszN NX\DXFZwW0GQR1XS
LB2241-RCC MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu2TWM2OD1yLkm5O|M1KM7:TR?= NH\rZZhUSU6JRWK=
SK-NEP-1 NEnkV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrTTWM2OD1zLkG0OFg2KM7:TR?= NH;wSnZUSU6JRWK=
LXF-289 NGDZfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\jTWM2OD1zLkG3NVU3KM7:TR?= MVvTRW5ITVJ?
EPLC-272H M1\pSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i1emlEPTB;MT6xO|I2PiEQvF2= NInXeVBUSU6JRWK=
COLO-684 NYOzVYhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TsXGlEPTB;MT6yN|czPSEQvF2= NUOzUG1vW0GQR1XS
ES1 NV;mNGYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nCSGlEPTB;MT6yOFA3PSEQvF2= MXnTRW5ITVJ?
DOHH-2 M1\6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjneHpKSzVyPUGuNlgzODNizszN NXPCZlRKW0GQR1XS
CTB-1 NVKwdGRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwMki5PUDPxE1? MlPlV2FPT0WU
G-401 NX3sWpJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwMkm3PVUh|ryP NXzkWnlGW0GQR1XS
LoVo MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwM{K1N|Qh|ryP M362SHNCVkeHUh?=
Ramos-2G6-4C10 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFwM{O3NFEh|ryP MXrTRW5ITVJ?
MFM-223 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwM{S0OlEh|ryP Mk\2V2FPT0WU
PA-1 NEDyWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDMTWM2OD1zLkO1NlY2KM7:TR?= MmPCV2FPT0WU
697 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTlcmVKSzVyPUGuN|c3OTZizszN MUTTRW5ITVJ?
QIMR-WIL M{XYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwNEmxNVYh|ryP M4S3dnNCVkeHUh?=
HOS Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjGTWM2OD1zLkS5OVU5KM7:TR?= M3;BenNCVkeHUh?=
DMS-273 M3PaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33iXmlEPTB;MT61NVk2QSEQvF2= NFT4Zo9USU6JRWK=
ME-180 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jHNWlEPTB;MT61Olg6OSEQvF2= MkjJV2FPT0WU
HCC2218 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwNkiyNlUh|ryP M3fCRnNCVkeHUh?=
CAL-54 M2rzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXzTWM2OD1zLkexNlQzKM7:TR?= MVrTRW5ITVJ?
OMC-1 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofpTWM2OD1zLke0Olc4KM7:TR?= NXziVXpMW0GQR1XS
COR-L105 NYXmOY9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXVWIxTUUN3ME2xMlc6PzN5IN88US=> NWLhfXlTW0GQR1XS
BV-173 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n4VmlEPTB;MT64NVA4PCEQvF2= MVzTRW5ITVJ?
RKO M3fQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\NcFlKSzVyPUGuPFcyODFizszN MmDBV2FPT0WU
SNU-387 NUTIOpBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFwOEi0NFYh|ryP NWPHXnpLW0GQR1XS
SW1088 M3LxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe0OIhjUUN3ME2xMlk1PjB4IN88US=> NF;XO3NUSU6JRWK=
Hs-578-T MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;ZeGlEPTB;Mj6xNVQ{OyEQvF2= NFzVdoFUSU6JRWK=
OC-314 NVuxSndST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJwMUWwPFYh|ryP MXTTRW5ITVJ?
RMG-I MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK3TI1KSzVyPUKuNVY{QThizszN NYjiSnBzW0GQR1XS
NCI-H1395 MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MliwTWM2OD1{LkG4NFkyKM7:TR?= MXHTRW5ITVJ?
GAMG M1XXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLFSZpwUUN3ME2yMlI{QDR3IN88US=> M1G1[HNCVkeHUh?=
LB1047-RCC NGT1S5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDIdWVtUUN3ME2yMlI1OzF5IN88US=> NXnTWYF1W0GQR1XS
MN-60 NXTEfJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\nU21sUUN3ME2yMlI6QTJ|IN88US=> M4K1V3NCVkeHUh?=
OAW-28 NX\3OYhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe0VGNEUUN3ME2yMlI6QTVzIN88US=> M4LVbHNCVkeHUh?=
NCI-H2228 NGCyN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fkcmlEPTB;Mj6zNVU2OiEQvF2= NYLq[WpSW0GQR1XS
ABC-1 MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHpTWM2OD1{LkOzNlU{KM7:TR?= M33YZnNCVkeHUh?=
LS-513 NYPNbWRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJwM{O0PFQh|ryP MXnTRW5ITVJ?
KS-1 NWD5UnA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXvfWpDUUN3ME2yMlM5OTlzIN88US=> M3zadHNCVkeHUh?=
NB69 NUW3bpJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS2UotKSzVyPUKuN|g6QDNizszN MVLTRW5ITVJ?
VM-CUB-1 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nGWGlEPTB;Mj6zPVA5OyEQvF2= MYPTRW5ITVJ?
D-423MG NVjFcGtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\mTWM2OD1{LkSxNFQ1KM7:TR?= NEnpUIdUSU6JRWK=
EW-18 M{DwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rxNGlEPTB;Mj60NVk{QSEQvF2= MkfBV2FPT0WU
YH-13 NEjwfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTkdmg4UUN3ME2yMlQ3OTV|IN88US=> NI\zZWNUSU6JRWK=
T-24 NV;icHZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJwNEe4PFEh|ryP Mne4V2FPT0WU
ES8 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJwNEmyPFch|ryP MVTTRW5ITVJ?
ES3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO1TWM2OD1{LkS5O|U6KM7:TR?= M2HzR3NCVkeHUh?=
RXF393 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwNkC0PFch|ryP NHXhPWVUSU6JRWK=
RPMI-8226 NX7WdpR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jwXmlEPTB;Mj62Nlk2OyEQvF2= NEfpSFVUSU6JRWK=
AGS M2r3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnKPHZCUUN3ME2yMlczOTN5IN88US=> MkjlV2FPT0WU
HCC1395 NYPGOVFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL2TWM2OD1{Lke1NVg4KM7:TR?= MljaV2FPT0WU
MV-4-11 MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILUblNKSzVyPUKuO|UzPjZizszN MofLV2FPT0WU
A204 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJwOEO4O|Ih|ryP NFLvfFZUSU6JRWK=
MCF7 MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjPUHZKSzVyPUKuPFYyOTdizszN NHSwblFUSU6JRWK=
SNU-423 NWXRPZFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJwOEmyOFIh|ryP NYLHNmRQW0GQR1XS
NCI-H1048 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TEbGlEPTB;Mj65Olg3PSEQvF2= NFnFSmxUSU6JRWK=
GR-ST NX7NZnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXrW2tqUUN3ME2zMlA1PjFzIN88US=> M{LYXnNCVkeHUh?=
EoL-1- NEHte5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DobmlEPTB;Mz6wO|A2QCEQvF2= M1frNHNCVkeHUh?=
HuH-7 MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkmzTWM2OD1|LkC5OFY1KM7:TR?= NEm4TmpUSU6JRWK=
OS-RC-2 NIn2ZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrYTYpwUUN3ME2zMlEyOTlizszN NWX6TW54W0GQR1XS
EW-3 NHLYU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX2TWM2OD1|LkG5OVI6KM7:TR?= M{fYfXNCVkeHUh?=
NCI-H747 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7rW|h4UUN3ME2zMlIxPjl2IN88US=> MnHSV2FPT0WU
EW-16 M2jjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLkTWM2OD1|LkKxPFc6KM7:TR?= M3f0XHNCVkeHUh?=
DOK NHj5NZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTGTWM2OD1|LkKyPFU6KM7:TR?= MUPTRW5ITVJ?
HCC2157 NFjFTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNwM{ixO|kh|ryP NGH4dWRUSU6JRWK=
OVCAR-3 NHjmdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{WxN2lEPTB;Mz60NFc5PiEQvF2= NWHiWmhlW0GQR1XS
NCI-H1623 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LGdGlEPTB;Mz60NVIzPCEQvF2= MmfEV2FPT0WU
H4 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNwNEW2NlYh|ryP MVLTRW5ITVJ?
SW1710 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3tRWVKSzVyPUOuOFY3PzhizszN MnnQV2FPT0WU
RT-112 NUTNOplRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP2SIFKSzVyPUOuOVI{QDhizszN Mn\wV2FPT0WU
DMS-114 M2SwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr2eY5KSzVyPUOuOlIzPzhizszN M4rO[nNCVkeHUh?=
AN3-CA MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLSdIFCUUN3ME2zMlYzPDV4IN88US=> NYPGeFNpW0GQR1XS
KNS-62 MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPFTWM2OD1|Lk[zN|M5KM7:TR?= NUXyVVB3W0GQR1XS
SJRH30 NXqwT2xmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlznTWM2OD1|Lk[5NVIzKM7:TR?= MUjTRW5ITVJ?
G-402 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LxUmlEPTB;Mz63NFcyOSEQvF2= MlnqV2FPT0WU
MHH-PREB-1 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XRS2lEPTB;Mz63NlA{QCEQvF2= NH;3ZmNUSU6JRWK=
P30-OHK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L2TGlEPTB;Mz64NFk4PiEQvF2= MVXTRW5ITVJ?
RVH-421 M1Pocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnmN4lKSzVyPUOuPFE4QDhizszN M3O3eXNCVkeHUh?=
LU-134-A MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjENI53UUN3ME2zMlg5PDJ6IN88US=> MmDSV2FPT0WU
ECC10 NWH6W|c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[zN|ZKSzVyPUOuPVM3OjJizszN MWTTRW5ITVJ?
TGW NGHKOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXFd2EzUUN3ME20MlAzOzB3IN88US=> MYrTRW5ITVJ?
MLMA NG\GXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;0ZmtIUUN3ME20MlAzQTZ4IN88US=> NXX4XnRUW0GQR1XS
SCC-25 NEnYN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13QXmlEPTB;ND6wOlU3PiEQvF2= NIOyPHdUSU6JRWK=
TYK-nu MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HTZWlEPTB;ND6wPVU{PCEQvF2= NUPKbGtYW0GQR1XS
LAMA-84 NHTIVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvrTWM2OD12LkG0NVkyKM7:TR?= MmTwV2FPT0WU
Calu-3 NHrKRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjVboZSUUN3ME20MlI1PDF4IN88US=> M{j4PXNCVkeHUh?=
NCI-H460 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTVfmpKSzVyPUSuNlY1PDNizszN MkTyV2FPT0WU
EGI-1 NETueZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDiTndKSzVyPUSuN|c4PzhizszN NUHOSJlWW0GQR1XS
NCI-H292 NV3QZ5J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTRwM{ixOFYh|ryP Mm\kV2FPT0WU
HCE-T NHv5OWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPmTWM2OD12LkSxOVc6KM7:TR?= NIfFNW1USU6JRWK=
EW-11 M3XXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4iwXWlEPTB;ND60NVg{QCEQvF2= M4qxWnNCVkeHUh?=
ATN-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTRwNESzNFQh|ryP M{PYenNCVkeHUh?=
NB5 M2XzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXwSoRKSzVyPUSuOVM3QTdizszN MkXSV2FPT0WU
KLE NHjNVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTRwN{CxPVgh|ryP MV;TRW5ITVJ?
CAL-39 NYDRNYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwN{KxOFYh|ryP MWTTRW5ITVJ?
TI-73 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPJTFB2UUN3ME20MlgxPjB7IN88US=> NXLE[Xh{W0GQR1XS
HO-1-N-1 NVrxc3ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTRwOUSyJO69VQ>? NF2yXIRUSU6JRWK=
786-0 M{nCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHoTGNKSzVyPUSuPVQ3PzNizszN MlnUV2FPT0WU
SK-N-DZ Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf1TWM2OD12Lkm2NVQzKM7:TR?= MWTTRW5ITVJ?
NCI-H446 Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOwTWM2OD13LkKwNFA6KM7:TR?= MXrTRW5ITVJ?
ETK-1 M362d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XF[mlEPTB;NT6yNVE3PSEQvF2= MX\TRW5ITVJ?
BT-20 NGnmb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHsZ2pKSzVyPUWuNlE{PTNizszN MYLTRW5ITVJ?
MEL-HO M32xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTVwM{ezN|Yh|ryP MWjTRW5ITVJ?
CAL-27 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi5Rml7UUN3ME21MlQ3OzN7IN88US=> Mkj2V2FPT0WU
SW872 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDzT3ZKSzVyPUWuOVk1OjhizszN MYLTRW5ITVJ?
RPMI-2650 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTVwNk[xPVkh|ryP MXPTRW5ITVJ?
PFSK-1 M{DmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInIeJlKSzVyPUWuO|I4OzJizszN NUKyTpozW0GQR1XS
SF295 M{TsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HYOGlEPTB;NT64NFY{OyEQvF2= MVTTRW5ITVJ?
Becker Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXnW2RyUUN3ME21Mlg3PDd{IN88US=> MWjTRW5ITVJ?
Saos-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XRb2lEPTB;NT64OlU{KM7:TR?= MU\TRW5ITVJ?
SK-OV-3 M{HhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTVwOUm4NVYh|ryP NYHXb2FmW0GQR1XS
VMRC-RCZ MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PE[2lEPTB;Nj6wPFc4OyEQvF2= NU\GbJJmW0GQR1XS
EW-22 NXTTNI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTZwMUm2OFkh|ryP MoP5V2FPT0WU
BT-474 M{TQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K0VmlEPTB;Nj6yN|Mh|ryP NUXJU5pnW0GQR1XS
BFTC-909 M4G1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrC[nljUUN3ME22MlMxOzR3IN88US=> NInmeGxUSU6JRWK=
NB12 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTZwM{mwO|Eh|ryP NWGyO4c6W0GQR1XS
D-263MG Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPiTWM2OD14LkS1NVY6KM7:TR?= M1zoWXNCVkeHUh?=
SNB75 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTZwNkCxOFMh|ryP MnnZV2FPT0WU
A704 MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyxNotKSzVyPU[uOlMxPiEQvF2= M2r0fnNCVkeHUh?=
NCI-H1693 MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnJeJBSUUN3ME22MlY{PjB2IN88US=> MmHSV2FPT0WU
LN-405 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHY[otKSzVyPU[uO|k3PzJizszN Mk\UV2FPT0WU
CHL-1 NHLQcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTCTWM2OD14LkiwNFc6KM7:TR?= NHTSPGVUSU6JRWK=
A498 M2TaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULiZWN2UUN3ME22MlgyQTZzIN88US=> MoXtV2FPT0WU
TE-12 NF\rSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHYenRKSzVyPU[uPFM5OTdizszN NEXZXWxUSU6JRWK=
TE-6 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTZwOUOwN|gh|ryP MmL5V2FPT0WU
AU565 NGjXTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfZTWM2OD14Lkm2PVU4KM7:TR?= NHvjRlBUSU6JRWK=
RD NVizfGZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrYfXpOUUN3ME22Mlk5Ojh2IN88US=> M3Hu[nNCVkeHUh?=
SW1463 NVSyS2N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLJTWM2OD15LkGxNVY5KM7:TR?= MmTQV2FPT0WU
LU-99A MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfKSGZ[UUN3ME23MlE1OzJ{IN88US=> NYfwOINpW0GQR1XS
NCI-H28 M1nZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvo[WZbUUN3ME23MlI6OjRizszN NWK3d2dkW0GQR1XS
MC-IXC NIPvPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTdwNEi1O|Yh|ryP MUDTRW5ITVJ?
GP5d MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHRWIhrUUN3ME23MlQ5PzZ2IN88US=> Mk\hV2FPT0WU
GB-1 NHrCcnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrDOFRKSzVyPUeuOVQ5ODRizszN Mn;tV2FPT0WU
CAL-33 M3nSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTJVVExUUN3ME23MlY3OjN|IN88US=> M3Wwc3NCVkeHUh?=
MSTO-211H Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojSTWM2OD15Lk[3N|M3KM7:TR?= MWTTRW5ITVJ?
TE-5 NYXBXo4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHjTWM2OD15Lke5N|M1KM7:TR?= MUXTRW5ITVJ?
D-566MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PQPGlEPTB;OD6wOFQzQSEQvF2= MWTTRW5ITVJ?
JVM-3 NGPiRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;0SIhmUUN3ME24MlE2OjZ6IN88US=> MVvTRW5ITVJ?
T98G MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uybmlEPTB;OD6xPFA3PyEQvF2= NHux[5RUSU6JRWK=
HCC1954 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnjcJczUUN3ME24MlQ2OTB2IN88US=> NFTTZ4tUSU6JRWK=
SF126 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXuTWM2OD16LkS1PVM3KM7:TR?= NHfOS|ZUSU6JRWK=
LB996-RCC MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv3TWM2OD16LkWzNlU4KM7:TR?= NFfhfodUSU6JRWK=
SKG-IIIa MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\kTWM2OD16Lk[zNFY6KM7:TR?= MX\TRW5ITVJ?
NCI-SNU-1 NF\PdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG0TWM2OD16Lk[0OlQ{KM7:TR?= M{DMVXNCVkeHUh?=
LB771-HNC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL6dJVKSzVyPUiuOlQ3QTZizszN M1znZnNCVkeHUh?=
SCC-4 NFfUbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrlTWM2OD16Lk[4NlE6KM7:TR?= MoH6V2FPT0WU
CAMA-1 M1zzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe4Om5EUUN3ME24Mlc4OTR4IN88US=> NXHPcZpyW0GQR1XS
D-502MG M2DkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nXZ2lEPTB;OD63PFYzQSEQvF2= MonqV2FPT0WU
ESS-1 NVPFVFBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRThwOEi3NFQh|ryP MnTBV2FPT0WU
HEC-1 NFzEVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnMToJKSzVyPUiuPFk5PjZizszN MlTxV2FPT0WU
NB10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\uO2hKSzVyPUmuNFIzOjRizszN NHS2Nm5USU6JRWK=
8505C NWrvbpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTlwMESyN|Ih|ryP MUjTRW5ITVJ?
EFO-27 M4jtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LMS2lEPTB;OT6xOlQyOiEQvF2= NXL0[2pRW0GQR1XS
HN NIHoPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTlwMU[2Nlgh|ryP NFnmU49USU6JRWK=
DSH1 NUO1TW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjvTZhKSzVyPUmuNlA5PyEQvF2= MkHNV2FPT0WU
NBsusSR MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL0TWM2OD17LkK3OFAzKM7:TR?= Mm\TV2FPT0WU
LS-123 M3\ZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj0UoxqUUN3ME25MlMyPzZzIN88US=> NFTDU2JUSU6JRWK=
SHP-77 NETLSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTlwM{m5N|Uh|ryP NEPVSJdUSU6JRWK=
ACN NGTVfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTlwNUOyO|ch|ryP M36wR3NCVkeHUh?=
U251 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLBTWM2OD17Lk[1OVQ1KM7:TR?= MmPRV2FPT0WU
A431 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTlwOECyN|gh|ryP M4nx[3NCVkeHUh?=
5637 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPxPGhPUUN3ME25Mlg1QTh2IN88US=> MmLvV2FPT0WU
MDA-MB-157 M{LKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXWbm9iUUN3ME25MlkzQDd6IN88US=> NWrVVnIyW0GQR1XS
A101D MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjMWmFCUUN3ME25Mlk6QTd2IN88US=> NH\YO|dUSU6JRWK=
YKG-1 MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfyXoVCUUN3ME2xNE4zODB4IN88US=> NFLy[2ZUSU6JRWK=
LAN-6 NYHSOHN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe5UG5FUUN3ME2xNE4zOTZ2IN88US=> M4r4SnNCVkeHUh?=
OVCAR-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj0SFlKSzVyPUGwMlI1OzNizszN NF7ueHVUSU6JRWK=
A549 NYfZZXl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HGVmlEPTB;MUCuN|k4OyEQvF2= NHmxbIFUSU6JRWK=
no-11 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFyLkSzOVMh|ryP NYfDbGREW0GQR1XS
SF539 NH\U[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni1TWM2OD1zMD65NFQyKM7:TR?= NYfVNZNsW0GQR1XS
A388 NYPNUnF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn1VoJKSzVyPUGxMlM5QTdizszN NH;Weo1USU6JRWK=
DEL M4PuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoroTWM2OD1zMT60NlQh|ryP MYjTRW5ITVJ?
SW954 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PyS2lEPTB;MUGuOFY3QCEQvF2= MkjBV2FPT0WU
TK10 NVT2PJlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\sVZJKSzVyPUGxMlUzPzFizszN M4frR3NCVkeHUh?=
SW756 NYKyWW9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITzPVdKSzVyPUGxMlUzQTRizszN M2DuWnNCVkeHUh?=
PC-3 NVLIRZFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPuXWJHUUN3ME2xNU42PzZ2IN88US=> MW\TRW5ITVJ?
ONS-76 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH5bFFKSzVyPUGxMlY{PiEQvF2= M3PvRXNCVkeHUh?=
A427 NXrNZW56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFzLkewPVMh|ryP NUPrNG5tW0GQR1XS
MEG-01 M1r3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHQNmJWUUN3ME2xNU44PTB7IN88US=> MV\TRW5ITVJ?
BB30-HNC MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFzLke5PFIh|ryP M3[ySnNCVkeHUh?=
NCI-H1299 NHe3WGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nWc2lEPTB;MUGuPFA6OyEQvF2= NWfWNIkyW0GQR1XS
GCT Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn30TWM2OD1zMT64NlI5KM7:TR?= MUDTRW5ITVJ?
D-247MG NXfaXVZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD5Z5E6UUN3ME2xNU46PjZ|IN88US=> M2DITnNCVkeHUh?=
CFPAC-1 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLkTWM2OD1zMT65O|gzKM7:TR?= NV:4NJlyW0GQR1XS
EKVX NGfXWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF{LkCzNVMh|ryP MVfTRW5ITVJ?
CAL-51 NVfCbXZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLJTWM2OD1zMj6wO|E3KM7:TR?= NWK4O|hTW0GQR1XS
BB49-HNC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF{LkGxO|ch|ryP MnezV2FPT0WU
RPMI-7951 NXLqc5lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M132VGlEPTB;MUKuNVg2PCEQvF2= NF[0WXFUSU6JRWK=
RH-1 NWjPOplFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDGTWM2OD1zMj6yNVg1KM7:TR?= MYXTRW5ITVJ?
BCPAP M{WxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3roVWlEPTB;MUKuOFc1QSEQvF2= NF;qZ49USU6JRWK=
GCIY NI[zbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF{LkWyNFkh|ryP M17ib3NCVkeHUh?=
KNS-81-FD MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X6V2lEPTB;MUKuOVg3QSEQvF2= M1jyVXNCVkeHUh?=
KYSE-140 MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS3TWM2OD1zMj64OVk2KM7:TR?= MnvOV2FPT0WU
Ca-Ski M4nmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF{LkmwOFEh|ryP MljKV2FPT0WU
TGBC1TKB NFrYcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLEeJpVUUN3ME2xNk46OTF3IN88US=> NVrTW|g5W0GQR1XS
HCC1187 NYf1Sm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPTTWM2OD1zMz6xPVEzKM7:TR?= MmLUV2FPT0WU
SJSA-1 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG2VlZKSzVyPUGzMlI{OjdizszN NIXNTpNUSU6JRWK=
CTV-1 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDWNWVLUUN3ME2xN{4{PDVizszN MlH6V2FPT0WU
WM-115 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m0emlEPTB;MUOuOlQ5OyEQvF2= NXnJXYxyW0GQR1XS
CHP-212 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPUeIJJUUN3ME2xN{46PzN7IN88US=> M{\hV3NCVkeHUh?=
SCC-15 NWS1SldjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf6TWM2OD1zMz65O|c2KM7:TR?= M1rHSnNCVkeHUh?=
BPH-1 M2DxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13OWmlEPTB;MUSuNVY3PCEQvF2= M3:wNXNCVkeHUh?=
SW780 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDyTWM2OD1zND61NFI2KM7:TR?= MmfRV2FPT0WU
NCI-H2291 MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF2LkW4O|gh|ryP M{LkbXNCVkeHUh?=
JEG-3 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS0R4lEUUN3ME2xOE43OzJ4IN88US=> NXPKdGVvW0GQR1XS
CAL-120 NFrEfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF2LkewNlch|ryP MkX2V2FPT0WU
NCI-H23 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPaS5l7UUN3ME2xOE44QTl5IN88US=> MWDTRW5ITVJ?
MS-1 NGLJZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[wNHFKSzVyPUG0Mlk3OTFizszN MlTaV2FPT0WU
PC-14 NIT1coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\QS5RKSzVyPUG0Mlk3PTRizszN NYDSXZM5W0GQR1XS
D-283MED MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX0TWM2OD1zNT6wNVEyKM7:TR?= NI\rVnhUSU6JRWK=
OE19 M1zpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInMcmxKSzVyPUG1MlE2PDFizszN M2roU3NCVkeHUh?=
CAS-1 NVTZTnNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKyTWM2OD1zNT60NVg1KM7:TR?= NFLaUmFUSU6JRWK=
NCI-H727 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS5TWM2OD1zNT60NlIyKM7:TR?= M{PBUXNCVkeHUh?=
SiHa M1zhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF3Lke1PVQh|ryP M2\hbnNCVkeHUh?=
BFTC-905 NU\ncJFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPRfVBKSzVyPUG1Mlc3QTRizszN MVLTRW5ITVJ?
MDA-MB-453 MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\jVnJKSzVyPUG2MlE3PDJizszN MmXsV2FPT0WU
HuP-T3 NHXYW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnxdWVIUUN3ME2xOk43Ozd|IN88US=> MWrTRW5ITVJ?
SK-LU-1 MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO2TWM2OD1zNj62PVU3KM7:TR?= NUHLZmZYW0GQR1XS
Detroit562 NGHlXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvTTWM2OD1zNj63N|E5KM7:TR?= MmXzV2FPT0WU
HCC1569 NXLSRW05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HYVWlEPTB;MU[uPFM{PyEQvF2= MkCzV2FPT0WU
SK-MES-1 NV\lb|VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfNTWM2OD1zNj64OFE6KM7:TR?= NIrmTmVUSU6JRWK=
BB65-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC2OXVKSzVyPUG3MlA1PzlizszN NW\Xd29nW0GQR1XS
LOXIMVI MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjD[nFKSzVyPUG3MlA4ODdizszN Ml\0V2FPT0WU
SW1783 M2\GTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDNWZk4UUN3ME2xO{4yOjhizszN NXrSd2hqW0GQR1XS
NH-12 NHnuXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrFTWM2OD1zNz6zN|A{KM7:TR?= NH3WR2pUSU6JRWK=
UACC-257 M4\rRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF5LkW1NVIh|ryP M1PRPHNCVkeHUh?=
KOSC-2 M2LrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFficGJKSzVyPUG3MlY4PTdizszN NEnnRXFUSU6JRWK=
KG-1 NHzaPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLCUm9SUUN3ME2xO{43QTN5IN88US=> NEC3bJFUSU6JRWK=
M059J MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;nXmlEPTB;MUeuO|A{KM7:TR?= NXPLPFY{W0GQR1XS
MHH-NB-11 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvOW2U3UUN3ME2xO{46Pjd|IN88US=> MlvnV2FPT0WU
EW-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTkU4l3UUN3ME2xPE4yOzh{IN88US=> NEfaVFRUSU6JRWK=
CAL-85-1 NFfCW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF6LkKzOVch|ryP NUPDbWl6W0GQR1XS
639-V NWLtTZJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWyTWM2OD1zOD6zN|U1KM7:TR?= MlHwV2FPT0WU
C32 MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF6LkS3Nlch|ryP MUHTRW5ITVJ?
KM-H2 NHTvR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\3[3hKSzVyPUG4MlUzOzJizszN NW\Pb5Z[W0GQR1XS
A253 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vTUGlEPTB;MUiuO|I5PiEQvF2= MnTQV2FPT0WU
NCI-N87 NF7rbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj3TWM2OD1zOD65NFA5KM7:TR?= NGX6e|NUSU6JRWK=
8-MG-BA NFHPOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK1Z|hKSzVyPUG5MlA3PDZizszN MUnTRW5ITVJ?
GI-ME-N NXnMbVA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXETWM2OD1zOT6xOVQ3KM7:TR?= MnzmV2FPT0WU
8305C NV\FdZc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF7LkKyPFYh|ryP NGjMWnlUSU6JRWK=
TE-8 NFf3[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\R[nNKSzVyPUG5MlMxOjRizszN MX3TRW5ITVJ?
KYSE-270 MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF65VmpKSzVyPUKwMlAzOTdizszN M3X6N3NCVkeHUh?=
HL-60 NFHrfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP3TWM2OD1{MD6wPVQyKM7:TR?= MYDTRW5ITVJ?
Mo-T NHfrUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\FTWM2OD1{MD6xOlY2KM7:TR?= MXrTRW5ITVJ?
NCI-H1355 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJyLkOzO|Qh|ryP MoToV2FPT0WU
HT-1080 M2f0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPSTWM2OD1{MD61OFk4KM7:TR?= NFfzOIVUSU6JRWK=
MIA-PaCa-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPFTWM2OD1{MD62PFg{KM7:TR?= NX\ucYtYW0GQR1XS
NCI-H441 NXq4fY5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJTWM2OD1{MD63N|c6KM7:TR?= MYPTRW5ITVJ?
LCLC-97TM1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TvSWlEPTB;MkCuPFE{PCEQvF2= M3nSb3NCVkeHUh?=
HT-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LLXmlEPTB;MkGuOVY{OSEQvF2= MmG1V2FPT0WU
22RV1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\HdGlEPTB;MkGuOVY5PSEQvF2= NELZVINUSU6JRWK=
LK-2 M3;LN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXnTWM2OD1{MT61PVU{KM7:TR?= MoT3V2FPT0WU
CW-2 NYfzfoJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW5TWM2OD1{MT62NFY6KM7:TR?= NHjKbJdUSU6JRWK=
KYSE-510 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\1TWM2OD1{MT62NFk2KM7:TR?= MXLTRW5ITVJ?
CGTH-W-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJzLkexOlYh|ryP NFjOTHNUSU6JRWK=
NCI-H661 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzPTWM2OD1{Mj6wN|Qh|ryP NVvibGkxW0GQR1XS
KU-19-19 NFfVVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7nS49KSzVyPUKyMlE3QTdizszN NYXyb2M3W0GQR1XS
NCI-H2122 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ{LkK0N|Ih|ryP MYjTRW5ITVJ?
NCI-H526 M{PPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFToeYRKSzVyPUKyMlM5QTVizszN MUDTRW5ITVJ?
NCI-H1650 MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDCTWM2OD1{Mj63OlQh|ryP Ml2zV2FPT0WU
AM-38 MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfoVJJzUUN3ME2yNk45Pjh7IN88US=> MVrTRW5ITVJ?
NCI-H2405 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDUTWM2OD1{Mz6yOVM{KM7:TR?= Mm\rV2FPT0WU
M14 M1zN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW0OHF7UUN3ME2yN{41ODh6IN88US=> M{HkPHNCVkeHUh?=
ES4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\tPWlEPTB;MkOuOFI{OiEQvF2= MWPTRW5ITVJ?
DJM-1 M{TQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnFTWM2OD1{Mz61NlM1KM7:TR?= NE\K[nZUSU6JRWK=
S-117 NIrtPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M362UWlEPTB;MkOuO|Y2OSEQvF2= MWTTRW5ITVJ?
MZ2-MEL NXz3V3E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfVNZZKSzVyPUKzMlc4PTlizszN NIfId5dUSU6JRWK=
SK-MEL-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fGdGlEPTB;MkOuPFE{OyEQvF2= MnHqV2FPT0WU
HCC1806 NUnENJpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DQPWlEPTB;MkOuPFcxQSEQvF2= MXXTRW5ITVJ?
NMC-G1 MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHCR4FUUUN3ME2yOE4zOjJ4IN88US=> M1\qOHNCVkeHUh?=
DK-MG M2fYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL5OpRKSzVyPUK0MlI6PCEQvF2= M3zmc3NCVkeHUh?=
SK-N-FI MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPsTWM2OD1{ND6zN|AzKM7:TR?= NUjzbWFCW0GQR1XS
KINGS-1 NIjDb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvDTlh4UUN3ME2yOE41QDd2IN88US=> M3rs[HNCVkeHUh?=
HCC2998 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCwTWM2OD1{ND60PFg2KM7:TR?= NWLZ[5k4W0GQR1XS
ALL-PO MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LpfmlEPTB;MkSuOlE6KM7:TR?= M3rySnNCVkeHUh?=
MPP-89 MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PXcGlEPTB;MkWuNFQ2QCEQvF2= NYfofGN5W0GQR1XS
NCI-H2342 Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljkTWM2OD1{NT6xPVU{KM7:TR?= NX3xNZZ4W0GQR1XS
TE-1 NYHrblNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ3LkO1OlMh|ryP NGX6OplUSU6JRWK=
RH-18 M{TpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEezOZhKSzVyPUK1MlU6OThizszN Mn23V2FPT0WU
HT-1376 NXn1VJBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJ3Lk[0OlUh|ryP M4H4dnNCVkeHUh?=
U-2-OS NHLJXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLMTWM2OD1{NT62PFg5KM7:TR?= MV3TRW5ITVJ?
BT-549 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y0[WlEPTB;MkWuPVAyOSEQvF2= NFHUfm5USU6JRWK=
NCI-H1755 NED6XHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm4ZXdZUUN3ME2yOU46QTR3IN88US=> NYT6TY5EW0GQR1XS
EW-13 NGHKe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIGyfm5KSzVyPUK2MlAzPzRizszN NIHCZ3ZUSU6JRWK=
NB13 NX\Q[2xsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD0WItUUUN3ME2yOk4xQTR7IN88US=> NEniZWVUSU6JRWK=
NUGC-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PWRWlEPTB;Mk[uNlExOyEQvF2= Mk\HV2FPT0WU
GMS-10 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorOTWM2OD1{Nj6yN|U{KM7:TR?= MlyyV2FPT0WU
CHP-134 NIftOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjsWWVKSzVyPUK2MlM5PjdizszN NEHS[pRUSU6JRWK=
SW962 M37GNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzkRZl[UUN3ME2yOk42ODJzIN88US=> NWLSfXl2W0GQR1XS
SNU-449 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:2eGlEPTB;MkeuNFgxOyEQvF2= MX;TRW5ITVJ?
HuP-T4 M2\ac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ5LkC4O|kh|ryP NILp[FlUSU6JRWK=
SW948 NUHnV3ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnrTWM2OD1{Nz6xN|Q1KM7:TR?= MlTKV2FPT0WU
NCI-H226 NX7IRnRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvPTWM2OD1{Nz60OVc5KM7:TR?= MlLMV2FPT0WU
SK-PN-DW M3fDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ5Lk[wNVIh|ryP MorNV2FPT0WU
GI-1 NHvCTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjITWM2OD1{Nz63NlEh|ryP MVTTRW5ITVJ?
CAL-12T MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXlclJKSzVyPUK4MlEyOTJizszN NH3CV3BUSU6JRWK=
YAPC MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm4dnBKSzVyPUK4MlI2PjRizszN NGTCbYdUSU6JRWK=
SNU-C2B NXTnV2JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ6LkK5OlQh|ryP MoLjV2FPT0WU
RCC10RGB NVe4eZVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HBNWlEPTB;MkiuOVQyPyEQvF2= MV;TRW5ITVJ?
ES7 NF\4SGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\QdJJ1UUN3ME2yPU4yPDZ3IN88US=> MX3TRW5ITVJ?
PANC-03-27 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXDTWM2OD1{OT60OFQh|ryP NVfhXXV[W0GQR1XS
ES6 NHW5N4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvK[VlbUUN3ME2yPU45OTV5IN88US=> NV7QdHlkW0GQR1XS
HT-1197 NVrjdIRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD2TWM2OD1|MD6wOVk5KM7:TR?= MVvTRW5ITVJ?
ZR-75-30 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;CWZRKSzVyPUOwMlI{QDNizszN M4rIcHNCVkeHUh?=
DB NVHvbVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNyLkS5OFIh|ryP NXXmTpBqW0GQR1XS
OCI-AML2 NFrzc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37GZmlEPTB;M{GuNFY6KM7:TR?= M1nL[3NCVkeHUh?=
NCI-H2170 M1XhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf6W3JKSzVyPUOxMlg2OTZizszN NGnleHRUSU6JRWK=
IST-MES1 NEPnRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\vVZFKSzVyPUOyMlI5QTdizszN MmPwV2FPT0WU
769-P MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;LcoZKSzVyPUOyMlM3PDFizszN MWHTRW5ITVJ?
COR-L23 M2OzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fJd2lEPTB;M{KuPVA4OyEQvF2= M2TqWnNCVkeHUh?=
SW626 M1TzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTN|LkG3O|Yh|ryP NULX[4JqW0GQR1XS
LU-139 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLuZZh1UUN3ME2zN{43PjB3IN88US=> NUfNbmZ3W0GQR1XS
HT-144 NYHJOmpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH1NpVKSzVyPUOzMlg3OyEQvF2= NUn4SWZrW0GQR1XS
CaR-1 NF62OGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrLWIFKSzVyPUOzMlk5OjJizszN NHz5bWFUSU6JRWK=
OE33 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrjTWM2OD1|ND6yPFU2KM7:TR?= Mnr2V2FPT0WU
COLO-800 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r6S2lEPTB;M{SuN|Y1PyEQvF2= NF70cFZUSU6JRWK=
NB14 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTN2LkS2PFQh|ryP MV\TRW5ITVJ?
KURAMOCHI NWXqeHNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13wcGlEPTB;M{[uNVE6QCEQvF2= MmLMV2FPT0WU
SW48 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf1N44{UUN3ME2zOk4zPDd2IN88US=> M{nnZXNCVkeHUh?=
Daoy NUL0dGpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTN4Lk[1N|gh|ryP MkXMV2FPT0WU
TGBC24TKB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTN4Lk[3JO69VQ>? MkXiV2FPT0WU
DU-4475 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLwTWM2OD1|Nj65NFM{KM7:TR?= M{\RZXNCVkeHUh?=
SW1417 MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTN6LkC1OVIh|ryP MXvTRW5ITVJ?
EFO-21 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe1Zm9JUUN3ME2zPE46OzR7IN88US=> NFjCOHNUSU6JRWK=
MG-63 NI\sco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rxb2lEPTB;M{muN|QzPCEQvF2= NGnhO2VUSU6JRWK=
LC-2-ad NIHkTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\3emlEPTB;M{muOVUyOiEQvF2= MoryV2FPT0WU
NOMO-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTPeo55UUN3ME2zPU45Ojd2IN88US=> MUfTRW5ITVJ?
COLO-741 NF;wUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTtTWM2OD12MD6xN|A1KM7:TR?= MUfTRW5ITVJ?
BxPC-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny1TWM2OD12MD61Olg3KM7:TR?= MXvTRW5ITVJ?
HSC-2 M1rFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TtcWlEPTB;NECuPVEyOyEQvF2= NFHKPYJUSU6JRWK=
UMC-11 M1niWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL2TWM2OD12MT6yOlMh|ryP NY[3[ZBMW0GQR1XS
HCC1937 NYTEUG1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7FVGtbUUN3ME20Nk44QDR|IN88US=> NIW1V2JUSU6JRWK=
Calu-6 MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm1U4dvUUN3ME20N{4zOzh{IN88US=> NVPiUVdTW0GQR1XS
NCI-H1573 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[wT2dKSzVyPUSzMlM1PzdizszN MXfTRW5ITVJ?
SK-N-AS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTR|Lk[wNVkh|ryP M3j4PXNCVkeHUh?=
PSN1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTR3LkK1OFgh|ryP M1LJU3NCVkeHUh?=
TE-11 NHz6cllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrifXJKSzVyPUS1MlQ5PDJizszN MYjTRW5ITVJ?
NCI-H1155 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTR3Lki5Olch|ryP M4WxZ3NCVkeHUh?=
KM12 M1uy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\zVmlEPTB;NEWuPVA4PiEQvF2= NYj0TYJWW0GQR1XS
RO82-W-1 M1q0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:5WGlEPTB;NE[uPVgzOiEQvF2= MX3TRW5ITVJ?
SW1573 NE\OfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\aUWlEPTB;NEeuN|c{PiEQvF2= NYGzbpVvW0GQR1XS
CAKI-1 NX3mfndDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjBPYZWUUN3ME20PE4zQDR3IN88US=> M{PCd3NCVkeHUh?=
U-118-MG NUDzOHFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXHUWxKSzVyPUS4MlM4ODJizszN MnjqV2FPT0WU
KYSE-520 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:2VGlEPTB;NEiuOFAyPiEQvF2= NHLiTnNUSU6JRWK=
HT55 MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7LV5NKSzVyPUS5MlE1PzRizszN MXfTRW5ITVJ?
ChaGo-K-1 MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTR7LkS3PVMh|ryP NEC0ZVFUSU6JRWK=
IA-LM NX;yUJE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTV2Lk[zNlIh|ryP M2D0fHNCVkeHUh?=
UACC-62 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTV3LkGwOFYh|ryP NFzQWIpUSU6JRWK=
MKN7 M1vv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTV4LkCyPFUh|ryP MmjRV2FPT0WU
HPAF-II MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfYTWM2OD13Nj60NFc{KM7:TR?= M2HVOXNCVkeHUh?=
NTERA-S-cl-D1 M3HSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXXTWM2OD13Nz63O|gh|ryP M3;TOHNCVkeHUh?=
FTC-133 NYriTYxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HreGlEPTB;NUiuNFk3QSEQvF2= NGn1eJRUSU6JRWK=
MHH-ES-1 NUDMUZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3To[2lEPTB;NUiuOFgyPCEQvF2= M2jNdXNCVkeHUh?=
JVM-2 Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj3PI5KSzVyPUW4Mlk2ODZizszN NXflOVdbW0GQR1XS
TCCSUP NY\BZ|dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnzcphmUUN3ME21PU42Ojd7IN88US=> NIf6PWpUSU6JRWK=
COLO-824 M17ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPhTWM2OD14MD6wO|E6KM7:TR?= NXjmfZRCW0GQR1XS
647-V Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPIcFdKSzVyPU[wMlE{PDdizszN NFyxXmxUSU6JRWK=
HD-MY-Z NE\UN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfFTWM2OD14MD61Nlk1KM7:TR?= MYrTRW5ITVJ?
LS-411N Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfLPZBKSzVyPU[xMlM6ODNizszN NGrOfFhUSU6JRWK=
NCI-H596 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjGTWM2OD14Mj63OFk3KM7:TR?= NHe5bWZUSU6JRWK=
C-33-A NVfiNJNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\T[WlEPTB;NkSuNFk2PyEQvF2= MYfTRW5ITVJ?
BHY MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDMTWM2OD14ND6xNlQ2KM7:TR?= NF3KZZBUSU6JRWK=
KGN NET6U2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nOcWlEPTB;NkSuOVUyPCEQvF2= M4nUO3NCVkeHUh?=
NCI-H1092 NHjDd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrpbI9KSzVyPU[1MlAxQTVizszN MlW4V2FPT0WU
MZ1-PC NXTrcYc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTZ3LkW2OFkh|ryP Ml7RV2FPT0WU
LB831-BLC MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HafmlEPTB;NkWuPFQ5OSEQvF2= MmfpV2FPT0WU
SW620 M4TnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHPUZdqUUN3ME22Ok4zODN7IN88US=> MVrTRW5ITVJ?
HuO-3N1 M1PjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPhTWM2OD14OD6zNlM5KM7:TR?= MWrTRW5ITVJ?
SK-HEP-1 NEC1V45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnW[WJKSzVyPU[5Mlk1QDZizszN NFLmbGZUSU6JRWK=
LCLC-103H NYXUOIVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTdyLk[3NFUh|ryP NHvLZY5USU6JRWK=
KYSE-70 M3u0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH0TGxyUUN3ME23NE44QDN3IN88US=> M{DkeXNCVkeHUh?=
Mewo MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuyUZZKSzVyPUexMlUxPSEQvF2= MVnTRW5ITVJ?
COLO-668 NELOb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\aWGlEPTB;N{GuPFQ2OSEQvF2= NXvVSnhCW0GQR1XS
NCI-H522 NX;RTVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGwXpFKSzVyPUeyMlM1OTNizszN MXvTRW5ITVJ?
NCI-H1437 M2myc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTLXWxKSzVyPUe0MlQxPDhizszN MVPTRW5ITVJ?
U-266 M1XCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTd3LkS1NVYh|ryP NWHlcXVvW0GQR1XS
MC116 NES1Vm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW2VWpKSzVyPUe1MlU4ODhizszN MnS2V2FPT0WU
PANC-10-05 NI[wbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TX[mlEPTB;N{euOFI1OyEQvF2= M335TXNCVkeHUh?=
KYSE-180 NUHVVGlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfZTWM2OD15Nz61OFU1KM7:TR?= NH\2T2tUSU6JRWK=
JAR NFnoeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjQTWM2OD15OT6wOVQ3KM7:TR?= MVvTRW5ITVJ?
CAL-62 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofVTWM2OD16MD6wPVUh|ryP NH;vfGdUSU6JRWK=
A3-KAW M3HFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInWWGdKSzVyPUiwMlIyPTRizszN NITqfmNUSU6JRWK=
PANC-08-13 NHKyeYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LoZWlEPTB;OEGuNVc3QCEQvF2= NGS1N|hUSU6JRWK=
HSC-3 NHniXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfHSYlKSzVyPUizMlMxPzFizszN NF7YfVBUSU6JRWK=
HTC-C3 NVGxNG9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC2WnJKSzVyPUizMlQ4ODJizszN NYTkfnc{W0GQR1XS
KY821 M2X0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTh2LkC4PVIh|ryP M{[wRXNCVkeHUh?=
DoTc2-4510 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPuRnl6UUN3ME24OE4zOTh3IN88US=> NV;wZ|lTW0GQR1XS
NCI-H1581 NXLIUG14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvrR5hKSzVyPUi1MlQ3PDFizszN MmO0V2FPT0WU
KARPAS-299 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zIPGlEPTB;OE[uNVk4PyEQvF2= M33J[nNCVkeHUh?=
IST-MEL1 NHHG[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjhTWM2OD16Nj64PFczKM7:TR?= M3rtOHNCVkeHUh?=
KP-N-YS Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrycGNKSzVyPUi5MlkxOjhizszN MXnTRW5ITVJ?
KYSE-410 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFny[ZVKSzVyPUmxMlQxPDJizszN M3LnW3NCVkeHUh?=
TE-10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\xUGlEPTB;OUGuOVYyOSEQvF2= M1PuOnNCVkeHUh?=
SK-MEL-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\2PGlEPTB;OUKuPVExPiEQvF2= NHzzUmdUSU6JRWK=
COLO-792 NWjqZplTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi0WHFPUUN3ME25OU4zPTZ2IN88US=> M1fJTnNCVkeHUh?=
SCH M1K0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXrS2lKSzVyPUm2MlM5PzdizszN M2jO[HNCVkeHUh?=
NCI-H1792 M1LhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTl4Lki5PVIh|ryP NGCzN3pUSU6JRWK=
NCI-H2029 NVraZ3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXY[VdRUUN3ME25Ok46PTZ4IN88US=> MUjTRW5ITVJ?
SW684 NVjZeXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ZTWM2OD17OD62OlU1KM7:TR?= Mn7ZV2FPT0WU
NCI-H209 NXKxSpBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\pTWM2OD1zMECuNVIyKM7:TR?= M{fGTXNCVkeHUh?=
HLE MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFyNT6yPFIh|ryP MUXTRW5ITVJ?
GOTO MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTBUZhwUUN3ME2xNFcvPzd5IN88US=> NF\hdG9USU6JRWK=
NCI-H1793 NYC5VXVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m4T2lEPTB;MUC5MlI5KM7:TR?= MlXVV2FPT0WU
D-392MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDsTWM2OD1zMUeuN|k5KM7:TR?= M4fSeHNCVkeHUh?=
SW1990 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPOUWV5UUN3ME2xNlAvQTVzIN88US=> NHLjdmpUSU6JRWK=
ML-2 NVrFZVk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\UTWM2OD1zMkGuOlc3KM7:TR?= NHLYRo1USU6JRWK=
NCI-H2452 M2qwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z5PWlEPTB;MUKyMlIyKM7:TR?= NHv0cWxUSU6JRWK=
SK-MEL-30 M2XNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrVTHNKSzVyPUGyN{4zPDRizszN NEfIZo1USU6JRWK=
SN12C NF\5fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF{ND6xO|Yh|ryP MUnTRW5ITVJ?
NCI-H1770 MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXlVoJrUUN3ME2xNlUvPTF2IN88US=> NGT3PWpUSU6JRWK=
SF268 NXPl[pI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF{Nj6xOVgh|ryP NFLGOIZUSU6JRWK=
BALL-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC4OIhKSzVyPUGyOk4zOyEQvF2= NF2xbFJUSU6JRWK=
COLO-679 M4XmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF62SIpKSzVyPUGyOk44PTNizszN Mk\DV2FPT0WU
A2780 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF{OD65PFgh|ryP M3LQZnNCVkeHUh?=
NCI-H1651 M{T1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF|MT6yOFMh|ryP Mn2zV2FPT0WU
NCI-H2087 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF|MT60PFMh|ryP NIDtbIFUSU6JRWK=
U-87-MG NHP0OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K0UGlEPTB;MUOzMlYxPCEQvF2= NUDkdm5tW0GQR1XS
LB2518-MEL MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\2TWM2OD1zM{WuPVk{KM7:TR?= M4WyWnNCVkeHUh?=
HCT-116 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3yTWM2OD1zM{euNlE4KM7:TR?= MlfiV2FPT0WU
Ca9-22 MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7VRmptUUN3ME2xN|kvQDN|IN88US=> NE\De5dUSU6JRWK=
COR-L88 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfQTWM2OD1zNEKuNVQh|ryP MlvjV2FPT0WU
CP50-MEL-B NGn4TXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF2ND61NFEh|ryP NU\x[pd7W0GQR1XS
OVCAR-8 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\Pe2lEPTB;MUS1MlY{PiEQvF2= MoXmV2FPT0WU
SK-MEL-3 M4D0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF2Nz64O|gh|ryP M3XSc3NCVkeHUh?=
GT3TKB MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjmZlRKSzVyPUG0PU46OjhizszN NXfrO|F{W0GQR1XS
KYSE-450 NWXjTW9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTjTWM2OD1zNUGuOVM6KM7:TR?= MkjJV2FPT0WU
CAPAN-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF3Mz6wOlQh|ryP MkPqV2FPT0WU
BEN NFmxcVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF3Mz65Nlgh|ryP NX3NS3lCW0GQR1XS
NCI-H1304 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHPTXFLUUN3ME2xOVQvPjl2IN88US=> NVPMd2JnW0GQR1XS
KU812 NXX2O217T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HmOWlEPTB;MUW4MlY4PCEQvF2= MV;TRW5ITVJ?
Capan-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF4MD61OVMh|ryP Mk\pV2FPT0WU
A673 NWXRZYNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHlTWM2OD1zNkGuO|A2KM7:TR?= M2LGOXNCVkeHUh?=
SAS MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK2TWM2OD1zNkKuOlc5KM7:TR?= MnfUV2FPT0WU
NY MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLWTWM2OD1zNkWuN|E1KM7:TR?= NYHMW|N4W0GQR1XS
HCE-4 M4jJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF4Nj64OFUh|ryP NHjxeFJUSU6JRWK=
MDA-MB-231 NVjvfZhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDJTWM2OD1zN{euOVA{KM7:TR?= MV\TRW5ITVJ?
no-10 NYfmNldxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmyU4pKSzVyPUG3PE4yOzRizszN M1TvS3NCVkeHUh?=
MZ7-mel MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF5OD60Olch|ryP MoDmV2FPT0WU
NCI-H82 M4G2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zqTGlEPTB;MUiwMlE3PSEQvF2= NGf0UnNUSU6JRWK=
CAL-72 Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSxTWM2OD1zOEWuNFU1KM7:TR?= MXHTRW5ITVJ?
NCI-SNU-5 M33m[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XzV2lEPTB;MUi2Mlg1KM7:TR?= M{XEOnNCVkeHUh?=
OVCAR-4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPlb5dKSzVyPUG4PE4{OzNizszN NYO4clBjW0GQR1XS
SCC-9 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF7MTFOwG0> NX\TW|k3W0GQR1XS
KYSE-150 NUDQcW13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33PeGlEPTB;MUmxMlg5QCEQvF2= MX\TRW5ITVJ?
HT-29 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j3O2lEPTB;MkCxMlIyOiEQvF2= NHzzTW9USU6JRWK=
COLO-678 NGXNNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfHTWM2OD1{MEGuOFUh|ryP NEeybHdUSU6JRWK=
NCI-H650 NVvwVoY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJyMj6xNFMh|ryP MlT4V2FPT0WU
HuCCT1 M33xPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36xdGlEPTB;MkC0MlIxQCEQvF2= MXXTRW5ITVJ?
SW1116 M4XFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\iSGlEPTB;MkC3MlA4PyEQvF2= MYHTRW5ITVJ?
DBTRG-05MG NIfXTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LtfGlEPTB;MkC3MlkxQSEQvF2= NH3pcmtUSU6JRWK=
SW982 NU\uRo9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjhU5U1UUN3ME2yNFcvQTR6IN88US=> NYfwWIRrW0GQR1XS
RCM-1 NFzoN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTqeXNpUUN3ME2yNVQvPzZ{IN88US=> MoPQV2FPT0WU
COLO-320-HSR NF;seIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\pTWM2OD1{MU[uNVI2KM7:TR?= NX23[ZJ4W0GQR1XS
KNS-42 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTETWM2OD1{MU[uOVc1KM7:TR?= NXnMbXhkW0GQR1XS
C2BBe1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTvTWM2OD1{M{GuPVA2KM7:TR?= NIDieVlUSU6JRWK=
CCRF-CEM MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonBTWM2OD1{NEOuO|k2KM7:TR?= M4jPO3NCVkeHUh?=
SH-4 MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPhTWM2OD1{NE[uNFkh|ryP M3nkOXNCVkeHUh?=
LS-1034 NF\oNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnRe|NKSzVyPUK0Ok4zPjZizszN MoDwV2FPT0WU
NCI-H2347 NVfuWY5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\3TWM2OD1{NEeuO|E{KM7:TR?= MVPTRW5ITVJ?
RPMI-8866 M2LObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJ2OT6yO{DPxE1? NGrQN4VUSU6JRWK=
GAK MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ3Mz6wNFIh|ryP MmLLV2FPT0WU
NB6 NHW3V4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDaTWM2OD1{N{CuNUDPxE1? NV21VXZJW0GQR1XS
COLO-680N NIHHXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7FXVVzUUN3ME2yO|IvPTJ5IN88US=> MlX6V2FPT0WU
RERF-LC-MS NUfYZ4N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDwSndoUUN3ME2yO|YvODB5IN88US=> NWnsOpBIW0GQR1XS
TGBC11TKB M4jjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHXVW1KSzVyPUK3PE4yPzhizszN NF\HZ2xUSU6JRWK=
C8166 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXifGl{UUN3ME2yO|gvPTB4IN88US=> NFu1Z4RUSU6JRWK=
HDLM-2 NYjuZlVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTOTWM2OD1{OUSuOFA6KM7:TR?= MWnTRW5ITVJ?
IGR-1 NFzxXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ7NT62OVkh|ryP NIixcJhUSU6JRWK=
FADU MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3BeYpIUUN3ME2yPVcvPTFizszN NGHOdVRUSU6JRWK=
L-428 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTPXoVKSzVyPUK5O{43OTZizszN MUjTRW5ITVJ?
LU-65 NYe5bm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f1VWlEPTB;M{C0MlMzKM7:TR?= NYq5e3pvW0GQR1XS
HEL NGTQ[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jHRmlEPTB;M{C5Mlk5OyEQvF2= Mn7YV2FPT0WU
NCI-H810 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rpbmlEPTB;M{GwMlU4KM7:TR?= NWHY[o06W0GQR1XS
C3A NUXlRlV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y1WGlEPTB;M{GxMlgxOiEQvF2= NGD3dmVUSU6JRWK=
NCI-H630 NHXWfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTN|Mj6yPVQh|ryP NV2wb5JWW0GQR1XS
KP-N-YN MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\XTWM2OD1|NEGuNVI{KM7:TR?= M4DK[XNCVkeHUh?=
MOLT-13 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXrfm5KSzVyPUO0Nk4{OjZizszN NH\3TZNUSU6JRWK=
NCI-H1993 MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN2Mj6zOlUh|ryP MVnTRW5ITVJ?
BE-13 M2XBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHwbYJKSzVyPUO0OE4yPjdizszN MXzTRW5ITVJ?
IST-SL1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzrTWM2OD1|NEeuOFAyKM7:TR?= NUTXc5dTW0GQR1XS
TE-9 Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DDWGlEPTB;M{[zMlU5QSEQvF2= M2P6RnNCVkeHUh?=
LU-135 M3r4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFezcYVKSzVyPUO2O{4xOzVizszN NFHuWJVUSU6JRWK=
T84 M4fsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf0XHpKSzVyPUO3OE44OTJizszN MUDTRW5ITVJ?
K-562 NHPDepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInScGdKSzVyPUO4N{4{PiEQvF2= M4XmOHNCVkeHUh?=
SBC-5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDL[mxsUUN3ME2zPFYvQTh3IN88US=> NUDxUndUW0GQR1XS
NB17 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN7Mj61PVYh|ryP M4P3S3NCVkeHUh?=
NCI-H2052 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK5dW9KSzVyPUO5PE41PzJizszN M4S2TnNCVkeHUh?=
HCC38 NEfybHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTRyMT61PVMh|ryP MX7TRW5ITVJ?
NCI-H69 NUHLWIdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTwNZJKSzVyPUS0NU4xQDNizszN MUjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 MK-2206和这些细胞毒素药剂联用作用于NCI-H292移植瘤,MK-2206显示出非常有效的抗癌活性。卵巢癌A2780移植瘤中,按动物体重,每千克处理240mg MK-2206,则可抑制70%以上的Akt1/2在苏氨酸308位点和丝氨酸473位点的磷酸化,导致肿瘤生长抑制率达到60%。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[3]

+ 展开

Akt激酶实验:

通过得到的GSK 生物素肽段基质测定Akt激酶。使用含镧系金属螯合物偶联单抗的均相时间分辨荧光(HTRF)测定肽段磷酸化程度,这种单抗专门作用于与链霉亲和素——藻蓝素(SA-APC)载体相结合的磷酸化作用,SA-APC载体可以结合到肽段的部分生物素上。当镧系金属螯合物与藻蓝素相接触时,无辐射的能量从镧系金属螯合物传递给藻蓝素,然后藻蓝素发射波值为655纳米的光线。工作液:100X 蛋白酶抑制剂混合物(PIC):1mg/ml苯甲脒,0.5 mg/ml 抑肽素, 0.5 mg/ml亮抑肽酶, 0.5 mg/ml 抑肽酶。10X实验 buffer: 500 mM HEPES(pH 为7.5), 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-甘油磷酸。抑制 buffer:50 mM HEPES(pH为7.3), 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM 标记的单抗, 0.0067mg/ml SA-APC。ATP/MgCl2工作液: 1X 实验buffer, 1 mM DTT, 1X PIC, 5% 甘油, 激活的Akt。肽段工作液:1X实验buffer, 1 mM DTT, 1X PIC, 5% 甘油 2 TM GSK生物素肽段。工作液加到合适的孔中,然后加入总负荷为16的 ATP/MgCl2,反应开始。含MK-2206的实验组和对照组加入总负荷为10的肽段工作液。然后加入总负荷为13的酶液,混匀。反应进行50分钟,然后加入总负荷为60的均相时间分辨荧光抑制buffer停止反应。阻断的反应在室温下温育30分钟以上,然后使用仪器读数。
细胞实验:

[2]

+ 展开
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6,和NCI-H460细胞
  • Concentrations: 0, 0.3, 1,和3 μM
  • Incubation Time: 72或96小时
  • Method:

    MK-2206溶解在DMSO中,在实验使用前用培养基稀释。细胞按2~3×103密度接种在96孔板上,温育24小时。MK-2206 (分为0, 0.3, 1,和3 μmol四组)处理细胞,72或者96小时后,测定细胞增殖情况。


    (Only for Reference)
动物实验:

[2]

+ 展开
  • Animal Models: 携带SK-OV-3, NCI-H292, HCC70, PC-3,和NCI-H460模型的雄性CD1裸鼠
  • Formulation: 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
15% Captisol
17 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 480.39
化学式

C25H21N5O.2HCl

CAS号 1032350-13-2
稳定性 powder
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • 回答:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • 问题 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • 回答:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Related Antibodies

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

相关Akt产品

Tags: 购买MK-2206 2HCl | MK-2206 2HCl供应商 | 采购MK-2206 2HCl | MK-2206 2HCl价格 | MK-2206 2HCl生产 | 订购MK-2206 2HCl | MK-2206 2HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID